Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs

  • Amid the continued evolution of the COVID-19 landscape, Galecto Inc GLTO said it would focus on the Phase 2 pipeline of fibrosis and cancer treatments, despite announcing positive preliminary topline results from an investigator-initiated trial examining GB0139 in COVID-19.
  • The trial included 41 hospitalized patients who did not require mechanical ventilation, of which 20 were randomized to the GB0139 arm.
  • GB0139 showed a favorable safety profile with no treatment-related serious adverse events reported. 
  • GB0139 had a positive trend on acute lung injury related to COVID-19. Patients who received GB0139 showed improved lung function with a significant decline in oxygen flow requirements than patients only receiving standard of care (SOC).
  • Patients showed improved inflammation and coagulation biomarkers.
  • In a posthoc subgroup analysis of patients with moderate to severe COVID-19 infection, there was a 21% reduction in mortality in patients treated with GB0139 vs. SOC. 
  • Price Action: GLTO shares are down 3.49% at $4.70 during the market trading session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefscancerCovid-19fibrosis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!